|Dr. Richard Murray||Pres, CEO & Director||845.1k||N/A||1959|
|Mr. Hugh M. Cole||Chief Bus. Officer & Head of Corp. Devel.||561.11k||N/A||1965|
|Dr. Elizabeth G. Trehu||Chief Medical Officer||555.66k||N/A||1960|
|Dr. James P. Allison||Founder||N/A||N/A||N/A|
|Dr. Thomas F. Gajewski||Founder||N/A||N/A||N/A|
|Dr. Robert D. Schreiber||Founder||N/A||N/A||N/A|
|Dr. Drew Mark Pardoll M.D., Ph.D.||Founder||N/A||N/A||N/A|
|Dr. Padmanee Sharma||Founder||N/A||N/A||N/A|
|Dr. Louis M. Weiner||Founder||N/A||N/A||1952|
|Ms. Kimberlee Cobleigh Drapkin CPA, CPA||CFO & Treasurer||N/A||N/A||1968|
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.